Israel Englander Lipocine Inc. Transaction History

Millennium Management LLC

14 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 15, 2023	BUY	$0.3 - $0.58 $36,805 - $71,157	122,685 Added 198.35%	184,538 $59,000
Q4 2022 Feb 14, 2023	SELL	$0.37 - $8.65 $4,154 - $97,130	-11,229 Reduced 15.36%	61,853 $24,000
Q3 2022 Nov 14, 2022	SELL	$0.49 - $7.65 $62,222 - $971,427	-126,984 Reduced 63.47%	73,082 $33,000
Q2 2022 Aug 15, 2022	BUY	$0.73 - $1.34 $146,048 - $268,088	200,066 New	200,066 $160,000
Q1 2021 May 17, 2021	SELL	$1.38 - $2.28 $34,225 - $56,546	-24,801 Closed	0 $0
Q4 2020 Feb 16, 2021	BUY	$1.2 - $1.69 $29,761 - $41,913	24,801 New	24,801 $34,000
Q3 2020 Nov 16, 2020	SELL	$1.21 - $2.23 $76,158 - $140,358	-62,941 Closed	0 $0
Q2 2020 Aug 14, 2020	BUY	$0.42 - $1.26 $2,689 - $8,069	6,404 Added 11.33%	62,941 $79,000
Q1 2020 May 14, 2020	BUY	$0.32 - $0.77 $1,813 - $4,363	5,667 Added 11.14%	56,537 $27,000
Q4 2019 Feb 14, 2020	BUY	$0.32 - $3.15 $8,645 - $85,100	27,016 Added 113.26%	50,870 $20,000
Q3 2019 Nov 14, 2019	BUY	$1.79 - $3.33 $42,698 - $79,433	23,854 New	23,854 $67,000
Q1 2018 May 15, 2018	SELL	$1.18 - $3.46 $157,917 - $463,044	-133,828 Closed	0 $0
Q4 2017 Feb 14, 2018	SELL	$3.36 - $4.35 $199,721 - $258,568	-59,441 Reduced 30.76%	133,828 $460,000
Q3 2017 Nov 14, 2017	BUY	$3.67 - $4.19 $709,297 - $809,797	193,269	193,269 $767,000

Ticker LPCN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 88,510,800
Market Cap $394M
Description
Lipocine Inc., a clinical-stage biopharmaceutical company, focuses on the development of pharmaceutical products for the treatment of neuroendocrine and metabolic disorders. The company's primary development programs are based on oral delivery solutions for poorly bioavailable drugs. Its lead product candidate is TLANDO, an oral testosterone rep...

Get notified when there are updates to the investment portfolio of Millennium Management LLC, based on Form 13F filings with the SEC.

Stay updated on Millennium Management LLC and Israel Englander with notifications on news.